These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 27559961)
1. Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study. Nylén H; Habtewold A; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E Medicine (Baltimore); 2016 Aug; 95(34):e4631. PubMed ID: 27559961 [TBL] [Abstract][Full Text] [Related]
2. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin. Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275 [TBL] [Abstract][Full Text] [Related]
3. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. Aklillu E; Zumla A; Habtewold A; Amogne W; Makonnen E; Yimer G; Burhenne J; Diczfalusy U Br J Pharmacol; 2021 Aug; 178(16):3294-3308. PubMed ID: 33155675 [TBL] [Abstract][Full Text] [Related]
4. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Wohl DA; Orkin C; Doroana M; Pilotto JH; Sungkanuparph S; Yeni P; Vanveggel S; Deckx H; Boven K Antivir Ther; 2014; 19(2):191-200. PubMed ID: 24430534 [TBL] [Abstract][Full Text] [Related]
5. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829 [TBL] [Abstract][Full Text] [Related]
6. Higher serum 25-hydroxyvitamin D concentrations are associated with active pulmonary tuberculosis in hospitalised HIV infected patients in a low income tropical setting: a cross sectional study. Musarurwa C; Zijenah LS; Mhandire DZ; Bandason T; Mhandire K; Chipiti MM; Munjoma MW; Mujaji WB BMC Pulm Med; 2018 May; 18(1):67. PubMed ID: 29739378 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients. Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860 [TBL] [Abstract][Full Text] [Related]
8. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. Yimer G; Ueda N; Habtewold A; Amogne W; Suda A; Riedel KD; Burhenne J; Aderaye G; Lindquist L; Makonnen E; Aklillu E PLoS One; 2011; 6(12):e27810. PubMed ID: 22162992 [TBL] [Abstract][Full Text] [Related]
10. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Brown TT; McComsey GA Antivir Ther; 2010; 15(3):425-9. PubMed ID: 20516561 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536 [TBL] [Abstract][Full Text] [Related]
12. Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations. Mugusi S; Habtewold A; Ngaimisi E; Amogne W; Yimer G; Minzi O; Makonnen E; Sudfeld C; Burhenne J; Aklillu E Front Pharmacol; 2020; 11():26. PubMed ID: 32116703 [TBL] [Abstract][Full Text] [Related]
13. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old. Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066 [TBL] [Abstract][Full Text] [Related]
14. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. Padmapriyadarsini C; Bhavani PK; Tang A; Kumar H; Ponnuraja C; Narendran G; Hannah E; Ramesh C; Chandrasekar C; Wanke C; Swaminathan S Int J Infect Dis; 2013 Dec; 17(12):e1154-9. PubMed ID: 24120216 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. Ngaimisi E; Minzi O; Mugusi S; Sasi P; Riedel KD; Suda A; Ueda N; Bakari M; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E; Diczfalusy U J Antimicrob Chemother; 2014 Dec; 69(12):3311-9. PubMed ID: 25096076 [TBL] [Abstract][Full Text] [Related]
16. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. Naidoo A; Chirehwa M; McIlleron H; Naidoo K; Essack S; Yende-Zuma N; Kimba-Phongi E; Adamson J; Govender K; Padayatchi N; Denti P J Antimicrob Chemother; 2017 May; 72(5):1441-1449. PubMed ID: 28175315 [TBL] [Abstract][Full Text] [Related]
17. Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy. Coelho L; Cardoso SW; Luz PM; Hoffman RM; Mendonça L; Veloso VG; Currier JS; Grinsztejn B; Lake JE Nutr J; 2015 Aug; 14():81. PubMed ID: 26283663 [TBL] [Abstract][Full Text] [Related]
18. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067 [TBL] [Abstract][Full Text] [Related]
19. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. Patel A; Patel K; Patel J; Shah N; Patel B; Rani S J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1166-9. PubMed ID: 15319677 [TBL] [Abstract][Full Text] [Related]